Skip to main content
SpringerLink
Log in

Macrophages in cancer metastases and their relevance to metastatic growth

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The dissemination of malignant cells throughout the body to form secondary growths is a highly complex process dependent upon both host and tumor cell properties. One potential defensive system which could influence the outcome of metastasis is the mononuclear phagocyte system. Although macrophages have been observed in essentially all primary and metastatic tumors examined regardless of histologic type or anatomic location, the biological significance of these observations is far from clear. What is clear, however, is that in most cases the effects of macrophages on tumor cells are not sufficient to alter progressive growth. Therefore, the presence of macrophages within metastases does not necessarily signify a protective host defensive response. On the other hand, macrophage-induced regression of established metastases can occur in vivo under certain conditions in which tumor-bearing mice are treated systemically with macrophage-activating agents. When mice bearing metastases are treated with macrophage-activating agents contained within liposomes, metastasis-associated macrophages are activated to the tumoricidal state and the metastatic lesions are simultaneously eradicated. Such a process of macrophage activation may have implications in determining successful approaches to the therapy of disseminated cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res (28): 149–250, 1978.

    Google Scholar 

  2. Evans R: Macrophages in syngeneic animal tumours. Transplantation (14): 468–473, 1972.

    Google Scholar 

  3. Alexander P, Eccles SA, Gauci CLL: The significance of macrophages in human and experimental tumors. II. Immune responses to tumors and their antigens: cellular and humoral mechanisms. Ann N Y Acad Sci (276): 124–133, 1976.

    Google Scholar 

  4. Wood GW, Morantz RA: Immunohistologic evaluation of the lymphoreticular infiltrate of human central nervous system tumors. JNCI (62): 485–491, 1979.

    Google Scholar 

  5. Svennevig JL, Svarr H: Content and distribution of macrophages and lymphocytes in solid malignant human tumors. Int J Cancer (24): 754–758, 1979.

    Google Scholar 

  6. Evans R: Macrophages in solid tumors. In: James K, McBride B, Stuart A (eds) The macrophage and cancer. Edinburgh, Econoprint, 1977, pp 321–339.

    Google Scholar 

  7. Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F: Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors. Int J Cancer (23): 157–164, 1979.

  8. Vose BM: Cytotoxicity of adherent cells associated with some human tumors and lung tissues. Cancer Immunol Immunother (5): 173–179, 1978.

  9. Eccles SA, Alexander P: Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature (250): 667–669, 1974.

    Google Scholar 

  10. Nash JRG, Price JE, Tarin D: Macrophage content and colony-forming potential in mouse mammary carcinomas. Br J Cancer (39): 478–485, 1981.

    Google Scholar 

  11. Talmadge JE, Key M, Fidler IJ: Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol (126): 2245–2248, 1981.

    Google Scholar 

  12. Evans R, Lawler EM: Macrophage content and immunogenicity of C57BL/6J and BALB/cByJ methylcholanthrene-induced sarcomas. Int J Cancer (26): 831–835, 1980.

    Google Scholar 

  13. Evans R, Eidlen DM: Macrophage accumulation in transplanted tumors is not dependent on host immune responsiveness or presence of tumor-associated rejection antigens. J Reticuloendothel Soc (30): 425–437, 1981.

    Google Scholar 

  14. Mantovani A: In vitro effects on tumor cells of macrophages isolated from an early-passage chemically-induced murine sarcoma and from its spontaneous metastases. Int J Cancer (27): 221–228, 1981.

    Google Scholar 

  15. Key M, Talmadge J, Fidler I: Lack of correlation between the progressive growth of spontaneous metastases and their content of infiltrating macrophages. J Reticuloendothel Soc (32): 387–396.

  16. Wood GW, Gollahon KA: T-lymphocytes and macrophages in primary murine fibrosarcomas at different stages in their progression. Cancer Res (38): 1857–1865, 1978.

    Google Scholar 

  17. Key M, Haskill JS: Immunohistologic evidence for the role of antibody and macrophages in regression of the murine T1699 mammary adenocarcinoma. Int J Cancer (28): 225–236, 1981.

    Google Scholar 

  18. Hart IR: The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol (97): 587–600, 1979.

    Google Scholar 

  19. Russell SW, Witz IP, Herberman RB: A review of data, problems and open questions pertaining to in situ tumor immunity. Contemp Top Immunobiol (10): 1–20, 1980.

    Google Scholar 

  20. Kripke ML: Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res (37): 1395–1399, 1977.

    Google Scholar 

  21. Dvorak HF, Dickersin GR, Dvorak AM, Manseau EJ, Pyne K: Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. JNCI (67): 335–345, 1981.

    Google Scholar 

  22. Cheung HT, Cantarow WD, Sundharadas G: Characteristics of a low-molecular weight factor extracted from mouse tumors that affect in vitro properties of macrophages. Int J Cancer (22): 344–352, 1979.

    Google Scholar 

  23. Snyderman R, Pike M: An inhibitor of macrophage chemtaxis produced by neoplasms. Science (192): 370–372, 1976.

    Google Scholar 

  24. Russell SW, McIntosh AT: Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. Nature (268): 69–71, 1977.

    Google Scholar 

  25. Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science (208): 1469–1471, 1980.

    Google Scholar 

  26. Fidler IJ, Sone S, Fogler WE, Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA (78): 1680–1684, 1981.

    Google Scholar 

  27. Churchill WHJr, Piessens WF, Sulis CA, David JR: Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigen become cytotoxic for tumor cells. J Immunol (115): 781–786, 1975.

    Google Scholar 

  28. Piessens WF, Churchill WHJr, David JR: Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. J Immunol (114): 293–299, 1975.

    Google Scholar 

  29. Hibbs JBJr, Lambert LHJr, Remington JS: Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis (124): 587–592, 1971.

    Google Scholar 

  30. Hibbs JBJr: Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst (53): 1487–1492, 1974.

    Google Scholar 

  31. Chedid L, Carelli L, Audibert F: Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc (26): 631–641, 1974.

    Google Scholar 

  32. Sone S, Fidler IJ: In vitro activation of tumoricidal properities in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol (57): 42–50, 1981.

    Google Scholar 

  33. Fidler IJ: In situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramy dipeptide is a thymus-independent process. J Immunol (127): 1719–1720, 1981.

    Google Scholar 

  34. Key ME, Talmadge J, Fogler WE, Bucana C, Fidler IJ: Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. JNCI (69): 1189–1198, 1982.

    Google Scholar 

  35. Schroit AJ, Fidler IJ: Stimulation of macrophage-mediated destruction of tumor cells by liposomes containing a lipophilic derivative of muramyl dipeptide. In: Serrou E (ed) Current concepts in human immunology and cancer immunomodulation. Amsterdam, Elsevier Press, 1982, pp 631–637.

    Google Scholar 

  36. Griswald DPJr: Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents. Cancer Chemother Rep (3): 315–323, 1972.

    Google Scholar 

  37. Hanna MGJr, Bucana C, Hobbs B, Fidler IJ: Morphological aspects of tumor cell cytotoxicity by effector cells of the macrophage-histiocyte compartment: in vitro and in vivo studies in BCG-mediated tumor regression. In: Fink M (ed) The macrophage in neoplasia. New York, Academic Press, 1976, pp 113–133.

    Google Scholar 

  38. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ: Analysis of the fate of systemically administered liposomes and implication for their use in drug delivery. Cancer Res (42): 1412–1422, 1982.

    Google Scholar 

  39. Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ: Biochemical, morphological, and ultrastructural studies in the uptake of liposomes by murine macrophages. Cancer Res (41): 487–494, 1981.

    Google Scholar 

  40. Key ME, Hoyer L, Bucana C, Hanna MGJr: Mechanisms of macrophage-mediated tumor cytolysis. Adv Exp Med Biol (146): 265–310, 1982.

    Google Scholar 

  41. Evans R: Further observations on the effect of cyclophosphamide on intratumor and periopheral leukocyte levels. Am J Pathol (99): 667–684, 1980.

    Google Scholar 

  42. Sadler TE, Jones PDE, Castro JE: The effects of altered phagocytic activity on growth of primary metastatic tumor. In: James K, McBride B, Stuart A (eds) The macrophage and cancer. Edinburgh, Econoprint, 1977, pp 155–163.

    Google Scholar 

  43. Jones PDE, Castro JE: Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum. Br J Cancer (35): 519–527, 1977.

    Google Scholar 

  44. Russell SW, Doe WF, McIntosh AT: Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. J Exp Med (146): 1511–1520, 1977.

    Google Scholar 

  45. Mantovani A, Giavazzi R, Polentarutti N, Spreafico F, Gavattini S: Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. Int J Cancer (25): 617–620, 1980.

    Google Scholar 

  46. Liotta LA, Gattozi C, Kleinerman J, Saidel G: Reduction of tumor cell entry into vessels by BCG-activated macrophages. Br J Cancer (36): 639–641, 1977.

    Google Scholar 

  47. Fidler I: Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res (34): 1074–1078, 1974.

    Google Scholar 

  48. Mantovani A: Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Int J Cancer (22): 741–746, 1978.

    Google Scholar 

  49. Evans F: Macrophage requirement for growth of a murine fibrosarcoma. Br J Cancer (37): 1086–1089, 1978.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Metastasis and Treatment Laboratory, NCI-Frederick Cancer Research Facility, P.O. Box B, 21701, Frederick, MD, USA

    Marc E. Key

Authors
  1. Marc E. Key
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Key, M.E. Macrophages in cancer metastases and their relevance to metastatic growth. Cancer Metast Rev 2, 75–88 (1983). https://doi.org/10.1007/BF00046906

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00046906

Keywords

Search

Navigation